Status:
COMPLETED
Pharmacokinetics and Safety of RV521 Formulations
Lead Sponsor:
Pfizer
Conditions:
Respiratory Syncytial Virus Infections
Eligibility:
All Genders
18-45 years
Phase:
PHASE1
Brief Summary
The main aims of the study are to assess the pharmacokinetics and safety of single doses of RV521 administered as two different formulations
Eligibility Criteria
Inclusion
- Willing to comply with protocol defined contraception requirements
- In good health with no history of major medical conditions
- A body mass index (BMI) of 18-25 kg/m\^2, inclusive
Exclusion
- Evidence of any clinically significant or currently active major medical condition
- Positive test for Hepatitis B surface antigen (HBsAg), Hepatitis C antibody (HCV Ab), or human immunodeficiency virus antibody (HIV Ab) at screening
- Not willing to comply with protocol defined restrictions for intake of drugs of abuse, alcohol, nicotine-containing products, medication (prescription, OTC, herbal, vitamins/minerals etc) and specified food and drink products
Key Trial Info
Start Date :
August 13 2019
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
September 9 2019
Estimated Enrollment :
9 Patients enrolled
Trial Details
Trial ID
NCT04065698
Start Date
August 13 2019
End Date
September 9 2019
Last Update
June 7 2024
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Richmond Pharmacology Ltd
London, United Kingdom, SE1 1YR